Revised March 2012
- Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence. Xie P, Kranzler HR, Krauthammer M, Cosgrove KP, Oslin D, Anton RF, Farrer LA, Picciotto MR, Krystal JH, Zhao H, Gelernter J. Biol Psychiatry. 2011 Sep 15;70(6):528-36.
- Reward, addiction, withdrawal to nicotine. De Biasi M, Dani JA. Annu Rev Neurosci. 2011;34:105-30. Review.
- The CHRNA5-A3-B4 gene cluster in nicotine addiction. Berrettini WH, Doyle GA. Mol Psychiatry. 2011 Oct 4. doi: 10.1038/mp.2011.122. [Epub ahead of print]
- Chromosome 20 Shows Linkage With DSM-IV Nicotine Dependence in Finnish Adult Smokers. Keskitalo-Vuokko K, Hällfors J, Broms U, Pergadia ML, Saccone SF, Loukola A, Madden PA, Kaprio J. Nicotine Tob Res. 2012 Feb;14(2):153-60. Epub 2011 Oct 29.
- A latent class analysis of DSM-IV and Fagerström (FTND) criteria for nicotine dependence. Agrawal A, Scherrer JF, Pergadia ML, Lynskey MT, Madden PA, Sartor CE, Grant JD, Duncan AE, Haber JR, Jacob T, Bucholz KK, Xian H. Nicotine Tob Res. 2011 Oct;13(10):972-81.
- A 3p26-3p25 genetic linkage finding for DSM-IV major depression in heavy smoking families. Pergadia ML, Glowinski AL, Wray NR, Agrawal A, Saccone SF, Loukola A, Broms U, Korhonen T, Penninx BW, Grant JD, Nelson EC, Henders AK, Schrage AJ, Chou YL, Keskitalo-Vuokko K, Zhu Q, Gordon SD, Vink JM, de Geus EJ, Macgregor S, Liu JZ, Willemsen G, Medland SE, Boomsma DI, Montgomery GW, Rice JP, Goate AM, Heath AC, Kaprio J, Martin NG, Madden PA. Am J Psychiatry. 2011 Aug;168(8):848-52.
- A twin association study of nicotine dependence with markers in the CHRNA3 and CHRNA5 genes. Maes HH, Neale MC, Chen X, Chen J, Prescott CA, Kendler KS. Behav Genet. 2011 Sep;41(5):680-90.
- Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials. King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, Kaprio J, Lerman C, Park PW. Neuropsychopharmacology 2012 Feb;37(3):641-50. Epub 2011 Nov 2.
- A latent class analysis of DSM-IV and Fagerström (FTND) criteria for nicotine dependence. Agrawal A, Scherrer JF, Pergadia ML, Lynskey MT, Madden PA, Sartor CE, Grant JD, Duncan AE, Haber JR, Jacob T, Bucholz KK, Xian H. Nicotine Tob Res. 2011 Oct;13(10):972-81.
- Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Ray R, Ruparel K, Newberg A, Wileyto EP, Loughead JW, Divgi C, Blendy JA, Logan J, Zubieta JK, Lerman C. Proc Natl Acad Sci U S A. 2011 May 31;108(22):9268-73.
- Association of the nicotine metabolite ratio and CHRNA5/CHRNA3 polymorphisms with smoking rate among treatment-seeking smokers. Falcone M, Jepson C, Benowitz N, Bergen AW, Pinto A, Wileyto EP, Baldwin D, Tyndale RF, Lerman C, Ray R. Nicotine Tob Res. 2011 Jun;13(6):498-503.
- Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. Strasser AA, Benowitz NL, Pinto AG, Tang KZ, Hecht SS, Carmella SG, Tyndale RF, Lerman CE.Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):234-8.
- Dissection of the Phenotypic and Genotypic Associations With Nicotinic Dependence. Chen LS, Baker TB, Grucza R, Wang JC, Johnson EO, Breslau N, Hatsukami D, Smith SS, Saccone N, Saccone S, Rice JP, Goate AM, Bierut LJ. Nicotine Tob Res. 2011 Nov 18. [Epub ahead of print]
- Rare missense variants in CHRNB4 are associated with reduced risk of nicotine dependence. Haller G, Druley T, Vallania FL, Mitra RD, Li P, Akk G, Steinbach JH, Breslau N, Johnson E, Hatsukami D, Stitzel J, Bierut LJ, Goate AM. Hum Mol Genet. 2012 Feb 1;21(3):647-55. Epub 2011 Oct 31.
- The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. Bloom J, Hinrichs AL, Wang JC, von Weymarn LB, Kharasch ED, Bierut LJ, Goate A, Murphy SE. Pharmacogenet Genomics. 2011 Jul;21(7):403-16. doi: 10.1097/FPC.0b013e328346e8c0.
- Common polymorphisms in FMO1 are associated with nicotine dependence. Hinrichs AL, Murphy SE, Wang JC, Saccone S, Saccone N, Steinbach JH, Goate A, Stevens VL, Bierut LJ. Pharmacogenet Genomics. 2011 Jul;21(7):397-402. doi: 10.1097/FPC.0b013e328346886f.
- Genetic vulnerability and susceptibility to substance dependence. Bierut LJ. Neuron. 2011 Feb 24;69(4):618-27. Review.
- Genetic association of bipolar disorder with the β(3) nicotinic receptor subunit gene. Hartz SM, Lin P, Edenberg HJ, Xuei X, Rochberg N, Saccone S, Berrettini W, Nelson E, Nurnberger J, Bierut LJ, Rice JP; NIMH Genetics Initiative Bipolar Disorder Consortium. Psychiatr Genet. 2011 Apr;21(2):77-84.
- The association of the alpha-5 subunit of the nicotinic acetylcholine receptor gene and the brain-derived neurotrophic factor gene with different aspects of smoking behavior. Breetvelt EJ, Numans ME, Aukes MF, Hoeben W, Strengman E, Luykx JJ, Bakker SC, Kahn RS, Ophoff RA, Boks MP. Psychiatr Genet. 2011 Oct 15. [Epub ahead of print]
- Uncovering hidden variance: pair-wise SNP analysis accounts for additional variance in nicotine dependence. Culverhouse RC, Saccone NL, Stitzel JA, Wang JC, Steinbach JH, Goate AM, Schwantes-An TH, Grucza RA, Stevens VL, Bierut LJ. Hum Genet. 2011 Feb;129(2):177-88.
- Nicotine withdrawal-induced negative affect is a function of nicotine dependence and not liability to depression or anxiety. Edwards AC, Kendler KS. Nicotine Tob Res. 2011 Aug;13(8):677-85.
- A population-based twin study of the genetic and environmental relationship of major depression, regular tobacco use and nicotine dependence. Edwards AC, Maes HH, Pedersen NL, Kendler KS. Psychol Med. 2011 Feb;41(2):395-405.
Attention
Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at
Looking for Treatment?
Use the SAMHSA Treatment Locator or 1-800-662-HELP.
Helpline open during government shutdown
Featured Publication
2010 Strategic Plan
Outlines NIDA’s drug abuse and addiction research strategic priorities for the next 5 years, focusing on prevention, treatment, HIV/AIDS, and other cross-cutting issues.